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Introduction
Familial hypercholesterolaemia (Online Mendelian 
Inheritance in Man number 143890) is a common 
autosomal-dominant disorder that is thought to be 
mono genic, and is characterised by substantially raised 
plasma concentrations of low-density lipoprotein chol-
esterol (LDL-C) and a ﬁ ve to eight times higher than 
average risk of early coronary heart disease.1 The 
National Institute for Clinical Health and Excellence 
(NICE)-endorsed Simon Broome Register criteria for a 
clinical diagnosis of familial hypercholesterolaemia 
include a high LDL-C concentration (>4·9 mmol/L in 
adults) plus a family history of raised cholesterol, or 
early coronary heart disease in a ﬁ rst-degree relative.1,2 
Patients who also have tendon xanthomas—a hallmark 
of long-term high cholesterol—are designated as 
having deﬁ nite familial hypercholesterolaemia, where-
as patients without tendon xanthomas are given the 
clinical diagnosis of possible familial hyper cholesterol-
aemia. The prevalence of familial hyper choles terol-
aemia is about 1 per 500 people in most countries in 
Europe, although this might be an underestimate 
because a population-based study reported a frequency 
of one per 137 in Denmark.3 120 000 people in the UK 
could therefore have heterozygous familial hyper-
cholesterol aemia with an increased coronary heart 
disease risk, but only around 15 000 are being treated 
in lipid clinics.4 
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Summary
Background Familial hypercholesterolaemia is a common autosomal-dominant disorder caused by mutations in three 
known genes. DNA-based cascade testing is recommended by UK guidelines to identify aﬀ ected relatives; however, 
about 60% of patients are mutation-negative. We assessed the hypothesis that familial hypercholesterolaemia can also 
be caused by an accumulation of common small-eﬀ ect LDL-C-raising alleles.
Methods In November, 2011, we assembled a sample of patients with familial hypercholesterolaemia from three UK-
based sources and compared them with a healthy control sample from the UK Whitehall II (WHII) study. We also 
studied patients from a Belgian lipid clinic (Hôpital de Jolimont, Haine St-Paul, Belgium) for validation analyses. We 
genotyped participants for 12 common LDL-C-raising alleles identiﬁ ed by the Global Lipid Genetics Consortium and 
constructed a weighted LDL-C-raising gene score. We compared the gene score distribution among patients with familial 
hypercholesterolaemia with no conﬁ rmed mutation, those with an identiﬁ ed mutation, and controls from WHII.
Findings We recruited 321 mutation-negative UK patients (451 Belgian), 319 mutation-positive UK patients 
(273 Belgian), and 3020 controls from WHII. The mean weighted LDL-C gene score of the WHII participants (0·90 
[SD 0·23]) was strongly associated with LDL-C concentration (p=1·4 × 10−⁷⁷; R²=0·11). Mutation-negative UK patients 
had a signiﬁ cantly higher mean weighted LDL-C score (1·0 [SD 0·21]) than did WHII controls (p=4·5 × 10−¹⁶), as did 
the mutation-negative Belgian patients (0·99 [0·19]; p=5·2 × 10−²⁰). The score was also higher in UK (0·95 [0·20]; 
p=1·6 × 10−⁵) and Belgian (0·92 [0·20]; p=0·04) mutation-positive patients than in WHII controls. 167 (52%) of 
321 mutation-negative UK patients had a score within the top three deciles of the WHII weighted LDL-C gene score 
distribution, and only 35 (11%) fell within the lowest three deciles.  
Interpretation In a substantial proportion of patients with familial hypercholesterolaemia without a known mutation, 
their raised LDL-C concentrations might have a polygenic cause, which could compromise the eﬃ  ciency of cascade 
testing. In patients with a detected mutation, a substantial polygenic contribution might add to the variable penetrance 
of the disease. 
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LDL-C concentrations in patients with familial hyper-
cholesterolaemia can be eﬀ ectively lowered by statins,5,6 
which can signiﬁ cantly improve life expec tancy.6–8 The 
charity HEART UK has written a report on the health, 
social, and economic advantages of treating familial 
hypercholesterolaemia,9 and estimated  that high-intensity 
lipid-lowering statin therapy would lead to 101 fewer 
cardiovascular deaths per 1000 patients with familial 
hypercholesterolaemia given treatment (aged 30–85 years) 
than if no treatment was given, and that the UK could save 
£378·7 million from cardiovascular events avoided if all 
relatives of index cases were identiﬁ ed and treated 
optimally over 55 years, equating to £6·9 million per year. 
The 2008 UK NICE guidelines for the identiﬁ cation 
and management of patients with familial hyper-
cholesterolaemia10 recommend that all patients with 
clinical and biochemical features of familial hyper-
cholesterolaemia should be oﬀ ered a DNA test to conﬁ rm 
their diagnosis.2 Mutation testing would then enable 
unambiguous identiﬁ cation of aﬀ ected relatives. This 
cascade testing strategy11 has been successfully applied in 
the Netherlands in families of familial hypercholesterol-
aemia probands with a detected mutation, thus allowing 
statin treatment of family members at risk of early 
coronary heart disease.12 A DNA-based cascade testing 
strategy for patients with this disorder has been 
implemented in Wales, Scotland, and Northern Ireland,4 
but has not been widely commissioned in England. 
Mutations in one of three genes are known to cause 
familial hypercholesterolaemia. In the UK, about 93% of 
identiﬁ ed mutations are in the gene encoding the receptor 
for LDL-C removal (LDLR), a further 5% are in APOB, 
which codes for apolipoprotein B (the major apoprotein 
component of LDL-C that acts as a ligand for the LDL 
receptor), and about another 2% are in PCSK9, which 
codes for a protein involved in the degradation of the LDL 
receptor.13,14 With standard molecular diagnostic tech-
niques, a familial hyper cholesterolaemia-causing muta-
tion can be detected in 20–30% of patients with possible 
familial hyper cholesterolaemia and 60–80% of patients 
with deﬁ nite familial hypercholesterolaemia.14–16 Roughly 
two-thirds of patients have possible familial hyper-
cholesterol aemia;5,14 thus, overall no mutations are 
detected in about 60% of tested patients with this dis-
order.14 This ﬁ nding has led to a search for additional 
familial hypercholesterolaemia-causing genes, using 
genome-wide linkage approaches17 and next-generation 
sequencing of all coding exons.18 However, a proportion of 
all clinically diagnosed cases of familial hyper cholesterol-
aemia could possibly be polygenic, due to the inheritance 
of a greater than average number of common LDL-C-
raising alleles (each causing a slight eﬀ ect) leading to an 
increase in LDL-C above the diagnostic cutoﬀ . The 
inclusion of probands with a polygenic rather than mono-
genic cause of hyper cholesterol aemia would reduce the 
eﬃ  ciency of any cascade screening programme, since 
much less than the expected 50% of ﬁ rst-degree relatives 
would be aﬀ ected. Therefore, identiﬁ cation and exclusion 
of individuals with polygenic hyperlipidaemia would 
enhance and enrich any cascade testing programme.
The Global Lipid Genetic Consortium (GLGC) meta-
analysis of genome-wide association studies identiﬁ ed 
several loci where common variants aﬀ ect LDL-C con-
centration,19 and results of another study20 showed that a 
proportion of individuals carrying several LDL-C-raising 
single nucleotide polymorphisms (SNPs) have LDL-C 
concentrations that exceed the diagnostic LDL-C 
threshold of 4·9 mmol/L (used to diagnose familial 
hypercholesterolaemia). 
We aimed to calculate gene scores, derived from 
12 common LDL-C-raising SNPs in 11 genes (two in 
APOE), in a sample of UK patients with European 
ancestry who had a clinical diagnosis of familial hyper-
cholesterolaemia with or without an identiﬁ ed familial 
hypercholesterolaemia-causing mutation and compare 
them with those of healthy men and women of European 
ancestry from the UK Whitehall II (WHII) cohort study to 
test the hypothesis that familial hypercholesterolaemia 
can be caused by an accumulation of common small-
eﬀ ect LDL-C-raising alleles. We also aimed to validate our 
results by repeating the analysis in a sample of patients 
with familial hypercholesterolaemia from Belgium. 
Methods
Patients
In November, 2011, we assembled our study sample, 
which consisted of all British patients with familial 
hypercholesterolaemia from three sources: the Simon 
Broome British Heart Foundation study,21 the Oxford 
familial hypercholesterolaemia study,22 and the Depart-
ment of Health familial hypercholesterolaemia audit 
project.14 For validation analyses, we also recruited 
Belgian patients with familial hypercholesterolaemia 
from one lipid clinic (Hôpital de Jolimont, Haine St-
Paul, Belgium).23 See appendix for further details on 
inclusion and diagnostic criteria used in each study. We 
used a healthy comparison group of white men and 
women from the UK Whitehall II study (appendix).24 
The Whitehall II study was approved by the University 
College London Research Ethics Committee and partici-
pants gave informed consent to each aspect of the study. 
All other studies from which we recruited our study 
samples received ethical approval from their respective 
ethics committees.  
Procedures 
We isolated genomic DNA from whole blood samples 
using standard methods.25 Details of mutation detection 
in LDLR, APOB, and PCSK9 genes are presented in the 
appendix. We then used standard methods (appendix) to 
genotype the selected SNPs.
For the gene score calculation—the primary endpoint of 
the study—we selected only the lead SNP from each locus, 
and if a SNP was associated with more than one lipid 
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fraction, we only included it if LDL-C was the lead trait 
(most strongly associated) for the SNP. For each individual, 
we calculated LDL-C-speciﬁ c gene scores using the 
weighted sum of the risk allele (ie, the LDL-C-raising 
allele). The weights used were the corresponding per-allele 
(risk) beta coeﬃ  cients reported by the GLGC (appendix).  
Statistical analysis 
We did linear regression of observed baseline LDL-C 
concentrations with the weighted LDL-C gene scores. 
We also calculated the risk ratio of having a measured 
LDL-C concentration of higher than 4·9 mmol/L by 
deciles of the GLGC weighted score in WHII controls. 
We used the statistical program R-2.14.2 to analyse 
the data.
Role of the funding source 
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
UK patients with familial hypercholesterolaemia WHII controls (n=3020)
FH with no known mutation 
(n=321)
FH with known mutation 
(n=319)
p value*
Men 73/156 (46·8%) 126/237 (53·2%) 0·47 2308/3020 (76·4%)
Age (years) 54·9 (13·9) (n=320) 49·5 (14·0) (n=316) 0·02 49·0 (6·0)
Pretreatment total cholesterol (mmol/L) 9·16 (4·92) (n=263) 10·28 (1·90) (n=246) 0·03 6·4 (1·1)
Pretreatment LDL-C (mmol/L) 5·87 (1·57) (n=71) 7·03 (1·49) (n=27) 0·002 4·4 (1·0)
Post-treatment LDL-C (mmol/L) 4·22 (1·58) (n=136) 5·49 (1·34) (n=237) 0·05 4·4 (1·0)
Post-treatment HDL-C (mmol/L) 1·42 (0·34) (n=67) 1·37 (0·36) (n=237) 0·35 1·4 (0·4)
Post-treatment triglycerides (mmol/L) 1·82 (0·86) (n=67) 1·33 (0·67) (n=237) 1·54×10−⁶ 1·4 (1·1)
Data are number (%) or mean (SD), unless otherwise stated. The denominators vary because these measurements were only available in patients not receiving lipid lowering 
therapy. WHII=Whitehall II. FH=familial hypercholesterolaemia. LDL-C=low-density lipoprotein cholesterol. HDL-C=high-density lipoprotein cholesterol. *We adjusted p values 
according to the study source that the patient belonged to using a two-way ANOVA; age (p=0·02), post-treatment LDL (p<0·0001), and post-treatment HDL (p<0·0001) 
signiﬁ cantly diﬀ ered between each familial hypercholesterolaemia cohort after adjustment for presence or absence of mutation; sex (p=0·39), pretreatment total cholesterol 
(p=0·30) and pretreatment LDL (p=0·62) did not diﬀ er signiﬁ cantly after adjustment. 
Table 1: Basic characteristics of UK participants
Chromosome 
number
Gene Minor allele Common 
allele
GLGC weight 
for score 
calculation
Minor allele frequency
FH with known 
mutation (n=319)
FH without known 
mutation (n=321)
WHII controls
(n=3020)
rs2479409 1 PCSK9 G* A 0·052 0·33 0·39 0·35
rs629301 1 CELSR2 G T* 0·15 0·19 0·12 0·21
rs1367117 2 APOB A* G 0·10 0·35 0·37 0·33
rs4299376 2 ABCG8 G* T 0·071 0·37 0·37 0·32
rs1564348 6 SLC22A1 C T* 0·014 0·19 0·17 0·17
rs1800562 6 HFE A G* 0·057 0·06 0·08 0·07
rs3757354 6 MYLIP T C* 0·037 0·21 0·17 0·21
rs11220462 11 ST3GAL4 A* G 0·050 0·14 0·13 0·13
rs8017377 14 NYNRIN A* G 0·029 0·48 0·47 0·48
rs6511720 19 LDLR T G* 0·18 0·10 0·08 0·13
rs429358 19 APOE† C T ·· 0·19 0·21 0·15
rs7412 19 APOE† T C ·· 0·04 0·03 0·08
ε2ε2 19 APOE ·· ·· −0·9 ·· ·· ··
ε2ε3 19 APOE ·· ·· −0·4 ·· ·· ··
ε2ε4 19 APOE ·· ·· 0·2 ·· ·· ··
ε3ε3 19 APOE ·· ·· 0 ·· ·· ··
ε3ε4 19 APOE ·· ·· 0·1 ·· ·· ··
ε4ε4 19 APOE ·· ·· 0·2 ·· ·· ··
LDL-C=low-density lipoprotein cholesterol. FH=familial hypercholesterolaemia. WHII=Whitehall II. G=guanine. A=adenine. T=thymidine. C=cytosine. *Risk alleles 
(LDL-C-raising). †APOE weights were based on haplotypic eﬀ ects taken from Bennet and colleagues’ study,26 as described in the Methods section of our study. 
Table 2: Global Lipid Genetic Consortium 12-SNP LDL-C gene score calculation  
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access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results 
We had complete genotype data for 640 UK patients with 
familial hypercholesterolaemia—308 from the Simon 
Broome British Heart Foundation study, 242 from the 
Oxford familial hypercholesterolaemia study, and 90 from 
the Department of Health familial hypercholesterolaemia 
audit project (appendix). Complete genotype data was 
available for 3020 healthy controls from the WHII study. 
319 (50%) UK patients with familial hypercholesterolaemia 
had a known mutation, and of these, 297 (93·1%) had 
mutations in LDLR, 16 (5·0%) in APOB, and 6 (1·9%) in 
PCSK9. The characteristics of the mutation-negative and 
mutation-positive patients with familial hyper cholesterol-
aemia and healthy controls are shown in table 1, and the 
characteristics of patients in each study sample are 
presented in the appendix. Total cholesterol, LDL-C, 
HDL-C, and triglyceride concentrations were available for 
all healthy controls and for some patients with familial 
hypercholesterolaemia receiving lipid-lowering treatment 
(table 1). Compared with mutation-positive patients, 
mutation-negative patients were older, but had lower 
pretreatment total cholesterol and LDL-C concentrations 
(table 1). We recorded no diﬀ erence in LDL-C concen-
trations between groups after statin treatment. In 
both familial hypercholesterolaemia groups, triglyceride 
concentrations were not raised in either group compared 
with the other, and none of the patients was likely to have 
a combined hyperlipidaemia phenotype.
The 12 SNPs used to deﬁ ne the LDL-C gene score are 
listed in table 2. The median number of risk alleles 
present in the WHII controls was 13 (range 6–20), with a 
mean of 12·7 (SD 2·0) risk alleles and a per-allele raising 
eﬀ ect of 0·12 mmol/L (95% CI 0·10–0·14; appendix). The 
mean weighted LDL-C gene score of the WHII 
participants was 0·90 (SD 0·23), and WHII individuals in 
the bottom decile (decile 1) of the LDL-C gene score 
distribution had a mean LDL-C concentration of 
3·76 mmol/L (0·95), whereas those in the top decile 
(decile 10) had a mean LDL-C concentration of 
4·90 mmol/L (0·99), the diagnostic cutoﬀ  point for 
familial hypercholesterolaemia (table 3). A 1 SD 
increment in the weighted LDL-C score was associated 
with 0·33 mmol/L (95% CI 0·30–0·37) higher LDL-C 
concentration (p=1·4×10−⁷⁷), explaining 11% of the 
variance in this trait (R²=0·11). This association was 
robust to adjustment for sex, age, lipid-lowering drug use, 
body-mass index, diabetes status, smoking status, and 
blood pressure (Beta 0·34, 95% CI 0·31–0·38). 
Participants from WHII in decile 10 of the LDL-C score 
distribution had a much higher likelihood than those in 
decile 1 of having observed LDL-C concentrations above 
the UK NICE recommended diagnostic threshold of 
4·9 mmol/L (table 3, ﬁ gure 1), with 146 (50%) of 292 
individuals in decile 10 having observed LDL-C 
concentrations of greater than 4·9 mmol/L compared 
with 35 (12%) of 295 individuals in decile 1 (table 3). 
Based on the combined GLGC risk allele eﬀ ects, and 
using the WHII population mean LDL-C concentration of 
4·4 mmol/L, 50 (17%) of 295 WHII individuals in decile 1 
of the LDL-C weighted score distribution had predicted 
LDL-C concentrations of greater than 4·9 mmol/L, 
whereas 126 (43%) of 292 WHII individuals in decile 10 
LDL-C weighted score in 
WHII controls
Measured LDL-C 
(mmol/L) in 
WHII controls, 
mean (SD)
WHII controls with 
LDL-C >4·9 mmol/L
Risk ratio 
(95% CI) of LDL-C 
>4·9 mmol/L* 
Mean (SD) Range Measured Predicted 
Decile 1 0·43 (0·14) −0·5 to 0·58 3·76 (0·95) 36/299 
(12%)
51/302 
(17%)
NA
Decile 2 0·66 (0·04) 0·58 to 0·73 3·99 (0·88) 43/296 
(15%)
69/302 
(23%)
1·21 (0·80–1·82)
Decile 3 0·77 (0·03) 0·73 to 0·81 4·21 (0·96) 71/300 
(24%)
82/302 
(27%)
1·97 (1·36–2·84)
Decile 4 0·85 (0·02) 0·81 to 0·88 4·34 (0·95) 85/298 
(29%)
88/303 
(29%)
2·37 (1·66–3·38)
Decile 5 0·91 (0·02) 0·88 to 0·93 4·36 (0·94) 80/300 
(27%)
94/302 
(31%)
2·21 (1·55–3·17)
Decile 6 0·96 (0·01) 0·94 to 0·98 4·48 (0·91) 96/298 
(32%)
100/302 
(33%)
2·68 (1·89–3·79)
Decile 7 1·00 (0·01) 0·98 to 1·02 4·50 (1·00) 102/295 
(35%)
106/302 
(35%)
2·87 (2·04–4·05)
Decile 8 1·05 (0·02) 1·02 to 1·08 4·56 (0·93) 96/292 
(33%)
108/301 
(36%)
2·73 (1·93–3·87)
Decile 9 1·12 (0·02) 1·08 to 1·16 4·68 (1·05) 120/294 
(41%)
118/302 
(39%)
3·39 (2·42–4·74)
Decile 10 1·23 (0·06) 1·16 to 1·46 4·90 (0·99) 148/295 
(50%)
130/302 
(43%)
4·17 (3·01–5·78)
Please see appendix for details of how we predicted the LDL-C values. LDL-C=low-density lipoprotein cholesterol. 
WHII=Whitehall II. NA=not applicable. *Decile 1 used as reference. 
Table 3: Outcome data in Whitehall II controls according to weighted LDL-C gene score deciles
Figure 1: Risk ratio of participants in the WHII population having LDL-C 
>4·9 mmol/L according to gene score decile  
LDL-C=low-density lipoprotein cholesterol. WHII=Whitehall II. *Decile 1 used 
as reference.
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were predicted to be above this threshold, which is similar 
to the proportions based on actual measured LDL-C in 
the WHII population of 12% versus 50% (table 3). This 
supports the validity of the 12-SNP weighted GLGC score 
in UK individuals.
The familial hypercholesterolaemia group without a 
known mutation had a signiﬁ cantly higher mean 
weighted LDL-C gene score of 1·0 (SD 0·21; p=4·5×10−¹⁶) 
than did WHII participants (ﬁ gure 2A). This suggests 
that a substantial proportion of the mutation-negative 
familial hypercholesterolaemia group’s raised LDL-C 
concentrations can be explained by co-inheritance of 
common LDL-C-raising SNPs. 64 (20%) of 321 patients 
with familial hypercholesterolaemia without a known 
mutation had a score that fell within decile 10 of the 
WHII LDL-C score distribution. 167 (52%) had a score 
within deciles 7–10, whereas only 35 (11%) had a score 
within deciles 1–3.
When we calculated the weighted LDL-C gene score in 
the familial hypercholesterolaemia group with a known 
mutation, the mean weighted score (0·95 [SD 0·20]) 
was signiﬁ cantly higher than the score in the WHII 
group (0·90 [0·23]; p=1·6 × 10−⁵; ﬁ gure 2B, 2C), but was 
signiﬁ cantly lower than that of the mutation-negative 
group (1·00 [0·21]; p=0·0014). This result suggests that 
even in patients with familial hypercholesterolaemia 
who have a detected causative mutation, their raised 
LDL-C concentrations have an additional polygenic 
component.
DNA was available from 451 patients with familial 
hypercholesterolaemia without a known mutation from 
one lipid clinic in Belgium, and 273 patients with familial 
hypercholesterolaemia with a known mutation from the 
same clinic. All patients had a cholesterol concentration 
above the 95th percentile for age and sex (appendix) and a 
family history of early cardiovascular disease. The mean 
weighted score of the mutation-negative Belgian patients 
(0·99 [SD 0·19]) was signiﬁ cantly higher than the score of 
the WHII participants (p=5·2 × 10−²⁰), with a smaller 
diﬀ erence in score between the mutation-positive patients 
(0·92 [0·20]) and the WHII group (p=0·04; appendix). 
The weighted score in the mutation-negative group was 
also signiﬁ cantly higher than in the mutation-positive 
group (p=4·0 × 10−⁶). Overall, 73 (16%) had a LDL-C gene 
score that fell within decile 10 of the WHII LDL-C gene 
score distribution, and 211 (46%) fell within deciles 7–10.
Discussion
The major ﬁ nding of our study is that a substantial 
proportion of the raised LDL-C concentrations measured 
in patients with a clinical diagnosis of familial hyper-
cholesterolaemia with no detected causative mutation 
might have a polygenic rather than a monogenic cause. 
This observation was replicated in an independent 
sample of patients with familial hypercholesterolaemia 
from Belgium. In patients with polygenic familial 
hypercholesterolaemia, cascade testing of their relatives 
will be compromised, because less than the 50% of 
relatives expected for a proband with monogenic disease 
will be aﬀ ected. If cascade testing was restricted to the 
40% (roughly) of patients with a clinical diagnosis of 
familial hypercholesterolaemia with an identiﬁ ed 
causative mutation, this would eliminate staﬀ  and 
screening costs associated with the remaining 60% of 
patients who would not beneﬁ t.  
Figure 2: Distribution of weighted LDL-C gene scores
(A) Whitehall II controls (WHII) versus patients with familial 
hypercholesterolaemia without a known mutation (FH/M−). (B) WHII controls 
versus patients with familial hypercholesterolaemia with a known mutation 
(FH/M+). (C) FH/M− versus FH/M+. In both patients with deﬁ nite familial 
hypercholesterolaemia (DFH) and those with possible familial 
hypercholesterolaemia (PFH), patients without a detected mutation had a 
signiﬁ cantly higher mean weighted LDL-C gene score than did those with a 
detected mutation (DFH/M+ 0·95 [SD 0·012] vs DFH/M− 1·03 [0·018], p=0·001; 
PFH/M+ 0·91 [0·043] vs PFH/M− 1·00 [0·015], p=0·03; appendix). 
LDL-C=low-density lipoprotein cholesterol.
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A WHII vs FH/M–
WHII mean score=0·90 (SD 0·23)
FH/M– mean score=1·00 (SD 0·21)
p=4·5×10–16 
WHII
FH/M–
WHII
FH/M+
FH/M+
FH/M–
B WHII vs FH/M–
WHII mean score=0·90 (SD 0·23)
FH/M+ mean score=0·95 (SD 0·20)
p=1·6×10–5 
+
–0·5 0 0·5 1·0 1·5
LDL-C weighted gene score
C FH/M+ vs FH/M–
FH/M+ mean score=0·95 (SD 0·20)
FH/M– mean score=1·00 (SD 0·21)
p=0·0014
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The second ﬁ nding is that, even in patients with familial 
hypercholesterolaemia with a detected causative mutation, 
an additional polygenic contribution might explain their 
highly increased LDL-C concentrations, a ﬁ nding con-
ﬁ rmed in the Belgian patient samples. This result partly 
explains the reduced penetrance reported in families with 
familial hypercholesterolaemia, whereby the relatives have 
a milder form of the disease with a lower mean LDL-C 
concentration than the proband.27 A polygenic component 
is also likely to contribute to the large overlap in LDL-C 
concentrations reported in mutation-carrier and non-
carrier relatives,28 since the proband has more than the 
average number of LDL-C-raising SNPs, but the inheri-
tance of these SNPs will be independent of each other and 
the causative major mutation.
The LDL-C gene score we used is based on GLGC data 
from more than 100 000 participants,19 and is therefore an 
unbiased and robust genetic instrument for LDL-C-raising 
alleles. The weighted score was strongly associated with 
LDL-C concentrations in the healthy men and women 
from the WHII study, with a 1·1 mmol/L (24%) diﬀ erence 
in LDL-C concentrations between those in the bottom and 
top score deciles, which is similar to the eﬀ ect achieved by 
taking a 40 mg daily dose of simvastatin.29 Although 
27 (75%) of the 36 GLCG consortium LDL-C SNPs were 
present on the genotyping array, to generate a LDL-C-
speciﬁ c score we initially only included SNPs for which 
LDL-C was the lead trait associated with the SNP. However, 
when we repeated the analysis using the full range of 
GLGC LDL-C-raising SNPs (plus the APOE haplotype; 
appendix), it explained a slightly higher proportion of the 
variation in LDL-C concentration, but did not materially 
improve discrimination (appendix), conﬁ rming that the 
addition of further SNPs with very small eﬀ ects to a gene 
score is unlikely to be useful. 
In patients with the strongest clinical suspicion of 
familial hypercholesterolaemia—ie, tendon xanthomas, 
providing a clinical diagnosis of deﬁ nite familial hyper-
cholesterolaemia—the mutation detection rate is between 
60–80%,14–16 and this rate could be improved if additional 
genes with rare mutations causing monogenic autosomal 
familial hypercholesterolaemia are identiﬁ ed. Together 
with the reduced price of whole genome sequencing, in 
the future additional rare familial hypercholesterolaemia-
causing mutations could be identiﬁ ed. A better deﬁ nition 
of familial hyper cholesterolaemia might expedite this 
process. A diagnosis of familial hypercholesterolaemia in 
the UK is based on the Simon Broome criteria—namely, 
LDL-C concentration of higher than 4·9 mmol/L, a family 
history of raised cholesterol or early coronary heart disease 
in a ﬁ rst-degree relative, or the presence of tendon 
xanthomas. Clearly, polygenic hypercholesterolaemia 
would not be excluded. Groups in the Netherlands12 and 
the USA30 have proposed other diagnostic scores, but these 
scores are also likely to include polygenic hyper-
cholesterolaemia. Additionally, no major diﬀ erences were 
reported in the speciﬁ city and sensitivity of these three 
diagnostic criteria used to correctly predict whether a 
causative mutation would be detected in patients with 
familial hypercholesterolaemia from Denmark.31
There are limitations to our study. The three genes in 
which rare mutations cause familial hyper cholestero-
laemia (LDLR, APOB, and PCSK9) also have GLGC 
LDL-C-raising common alleles, and the inclusion of 
these SNPs could have biased the results in the unlikely 
event that they show linkage disequilibrium with 
undetected rare familial hypercholesterolaemia-causing 
mutations. However, we can rule this out because when 
we repeated the analysis excluding the three SNPs in 
these genes in the score, the ﬁ ndings were not 
substantially aﬀ ected (appendix).
We have not carried out a complete gene screen of 
PCSK9, nor for all the introns of LDLR, and we examined 
only the region of the APOB gene where familial 
hypercholesterolaemia-causing mutations have been 
reported. Therefore, some of the mutation-negative 
group could have an undetected mutation in one of these 
three genes, and this might explain why a proportion of 
the patients had a low LDL-C SNP score. The use of more 
LDL-C-raising SNPs or of other functional variants such 
as copy number variants might improve the dis-
criminatory power of the score, but increasing the 
number of GLGC-reported LDL-C SNPs in the score had 
only a marginal, non-signiﬁ cant improvement. Because 
the accepted frequency of familial hypercholesterolaemia 
in the general population is 1 in 500,1 six or seven of the 
3020 WHII participants were likely to have had 
undiagnosed familial hypercholesterolaemia, and if they 
had been identiﬁ ed and excluded from the study, we 
would have had a cleaner control sample, which might 
have marginally improved discrimination between the 
WHII participants and the familial hypercholesterolaemia 
groups. The mean total cholesterol concentration of 
6·4 mmol/L in the WHII participants is typical of the 
general population in the late 1980s when these 
participants were recruited, and concentrations were 
only marginally lower more than a decade later, with the 
Health Survey of England 200332 reporting mean total 
cholesterol concentrations of men and women aged 
45–54 years to be 5·9 mmol/L and 5·8 mmol/L, 
respectively (with the 90th percentile cutoﬀ s being 
7·3 mmol/L and 7·2 mmol/L, respectively). Since the 
WHII control sample cholesterol concentration falls 
within this range, it is probably representative of the 
current population. The replication of the eﬀ ect in an 
independent sample of familial hypercholesterolaemia 
patients, selected with diﬀ erent criteria, validates the 
ﬁ ndings, and although we did not have a sample of 
healthy Belgian participants for comparison, SNP 
frequencies are not likely to diﬀ er greatly between the 
two countries, since the GLGC SNP frequencies are 
representative of populations of European origin, and the 
comparison between the Belgian mutation-negative and 
mutation-positive groups was also statistically signiﬁ cant. 
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Our ﬁ ndings have relevance for the management of 
patients with familial hypercholesterolaemia (panel). All 
individuals with raised LDL-C concentrations qualify for 
statin treatment, whether or not their high cholesterol 
concentration has a mainly monogenic or polygenic 
cause. Results of modelling suggest that because patients 
with familial hypercholesterolaemia have a life-long 
burden of LDL-C accumulation, these patients need 
intensive lipid-lowering therapy, and although this 
treatment is more expensive than non-intensive therapy, 
it is cost eﬀ ective.33 However, patients with no detected 
mutation have lower mean LDL-C concentrations and 
coronary heart disease risk,15,34,35 and less atherosclerosis 
in their carotid arteries,36 than do patients with clinically 
diagnosed familial hypercholesterolaemia and a detected 
mutation. Although further research is needed, NICE-
recommended intensive lipid-lowering therapy might 
only be cost eﬀ ective in patients with familial hyper-
cholesterolaemia with a known mutation. 
The other NICE recommendation that might need to 
be examined in view of these data is that cascade testing 
in mutation-negative patients with familial hyper-
cholester olaemia is also cost eﬀ ective and should be done 
using LDL-C measures with so-called aﬀ ected status (to 
identify individuals for secondary cascading) identiﬁ ed 
by age-speciﬁ c and gender-speciﬁ c thresh olds.28 When a 
proband’s raised LDL-C is polygenic, the proportion of 
their relatives who are likely to also have raised LDL-C is 
substantially less than the 50% predicted for monogenic 
familial hypercholester olaemia. In one study,11 the 
proportion of relatives with LDL-C above the NICE 
recommended cutoﬀ  value was only 30%, and further 
cascade testing from these individuals (eg, their children) 
would be even less eﬀ ective. Family studies will need to 
be done to identify the score threshold above which 
cascade testing from mutation-negative patients with 
familial hypercholesterolaemia (more than 60% of all 
those with a clinical diagnosis of familial hyper-
cholesterolaemia in UK lipid clinics) will no longer be 
cost eﬀ ective. Based on the probability distribution 
shown in ﬁ gure 1, we propose that cascade testing from 
these patients should be restricted to those in the bottom 
20% of the distribution (ie, with a score lower than 0·73) 
who are highly unlikely to have an LDL-C concentration 
of greater than 4·9 mmol/L that can be explained by the 
inheritance of LDL-C-raising SNPs. The successful 
cascade testing programme running in the Netherlands 
is based entirely on families in which a familial 
hypercholesterolaemia-causing mutation has been 
detected.12 We therefore propose the diagnostic workﬂ ow 
shown in ﬁ gure 3. Patients with familial hyper-
cholesterolaemia who have no detected LDLR/APOB/
PCSK9 mutation and an LDL-C weighted gene score 
below 0·73 are highly likely to have an unidentiﬁ ed 
monogenic cause, which would warrant family 
studies and further research. If the next-generation 
sequenc ing library capture of the known familial 
hypercholesterolaemia-causing genes were expanded to 
include fragments containing the 12 SNPs, this infor-
mation could be obtained at essentially no additional 
cost. The actual usefulness of these cutoﬀ s for triaging 
Panel: Research in context
Systematic review
In 2008, the National Institute for Clinical Health and Excellence published the results of 
their systematic review of the identiﬁ cation and management of familial 
hypercholesterolaemia. This report recommended that all patients with clinical and 
biochemical features of this disorder should be oﬀ ered a DNA test to conﬁ rm their 
diagnosis and enable unambiguous identiﬁ cation of aﬀ ected relatives through a 
systematic cascade testing strategy. However, in roughly half of patients with a clinical 
diagnosis of familial hypercholesterolaemia, a causative mutation cannot be found. In 
2011, we used the meta-analysis data of genome-wide association studies including more 
than 100 000 individuals published by the Global Lipid Genetic Consortium (GLGC) to 
identify possible loci where common variants inﬂ uence LDL-C concentration. The 
combined information from these single nucleotide polymorphisms (SNPs) was then 
used as a genetic instrument, since we predicted that in individuals carrying several 
LDL-C-raising SNPs, LDL-C concentrations would exceed the diagnostic LDL-C threshold of 
4·9 mmol/L used in the diagnosis of familial hypercholesterolaemia.
Interpretation
In a substantial proportion of patients with familial hypercholesterolaemia in whom no 
mutation can be identiﬁ ed, their raised LDL-C probably has a polygenic cause. This 
compromises the eﬃ  cacy of cascade testing in this group, and such testing should be 
restricted to mutation-positive patients, as is done in some countries already. We propose 
that the clinical diagnosis of familial hypercholesterolaemia should be restricted to those 
in whom a mutation can be identiﬁ ed, whereas those with no detected mutation should 
be given the clinical diagnosis of polygenic hypercholesterolaemia. Even in patients with 
familial hypercholesterolaemia with a detected causative mutation, a substantial 
polygenic contribution occurs, which might explain the variable penetrance of the 
disease, and suggests that polygenes might contribute to diseases formerly considered to 
be solely monogenic. 
Figure 3: Diagnostic workﬂ ow for cascade testing in patients with familial hypercholesterolaemia 
FH=familial hypercholesterolaemia. SNP=single nucleotide polymorphism. LDL-C=low-density lipoprotein 
cholesterol. *As recommended by NICE.27  
Individual with clinical diagnosis
of deﬁnite or possible FH
High probability of polygenic 
hypercholesterolaemia
Do not cascade
(low detection of aﬀected relatives)
Next-generation sequence of 
FH genes OR whole exome sequence
No FH-causing mutation 
detected
Determine 12-SNP LDL-C 
gene score
Low probability of polygenic 
hypercholesterolaemia
Cascade with LDL-C 
concentrations and diagnostic 
cutoﬀs;* continue search for 
monogenic cause of FH
FH-causing mutation detected 
in LDLR/APOB/PCSK9
Use mutation to cascade test all 
ﬁrst-degree relatives
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probands needs to be researched further to establish the 
proportion of aﬀ ected relatives in the two groups.  
Would it, therefore, be clinically useful to restrict the 
clinical diagnosis of familial hypercholesterolaemia to 
those patients in whom a causative major gene mutation 
can be identiﬁ ed? We propose that, from this perspective, 
patients with a familial hypercholesterolaemia phenotype 
and no such mutations could be given the clinical diagnosis 
of polygenic hypercholesterolaemia, and not familial 
hypercholesterolaemia. This should not, how ever, aﬀ ect 
the treatment of these patients,37 but would inﬂ uence the 
decision to undertake cascade testing in their relatives. 
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